Evidence map›Paper›PMID 24180433›Full record

ReviewCritical reviews in toxicology2014

Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator.

Clifford R Elcombe, Richard C Peffer, Douglas C Wolf, Jason Bailey, Remi Bars, David Bell, Russell C Cattley, Stephen S Ferguson, David Geter, Amber Goetz and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in Critical reviews in toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
26.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 259 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Systematic evaluation of the evidence base on ethylCurrent research in toxicology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Dose-response modeling of effects in mice after exposure to a polyfluoroalkyl substance (Nafion byproduct 2).Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 15 institutions in 8 countries.

Clifford R ElcombeCXR Biosciences Ltd , Dundee , UK .
Richard C Peffer
Douglas C Wolf
Jason Bailey
Remi Bars
David Bell
Russell C Cattley
Stephen S Ferguson
David Geter
Amber Goetz
Jay I Goodman
Susan Hester
Abigail Jacobs
Curtis J Omiecinski
Rita Schoeny
Wen Xie
Brian G Lake
Research Triangle Park Foundation · USAgroscope · CHAuburn University · USBayer (Germany) · DECenter for Drug Evaluation and Research · USDow Chemical (India) · INEnvironmental Protection Agency · USEuropean Chemicals AgencyMichigan State University · USPennsylvania State University · USPharmacoGenetics (China) · CNSyngenta (Switzerland) · CHSyngenta (United States) · USThermo Fisher Scientific (Norway) · NOUniversity of Surrey · GB

Funding

Targeting Dynamics of CAR and PXR in the Mouse and Human GenomesR01GM066411 · NIGMS · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI OMIECINSKI, CURTIS J · 2002 to 2017
$4.5M
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic SyndromeR01DK083952 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, WEN · 2010 to 2019
$3.0M
NIDDK NIH HHS R01 DK083952NIGMS NIH HHS R01 GM066411
6 · The paper itself

Abstract

The constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are important nuclear receptors involved in the regulation of cellular responses from exposure to many xenobiotics and various physiological processes. Phenobarbital (PB) is a non-genotoxic indirect CAR activator, which induces cytochrome P450 (CYP) and other xenobiotic metabolizing enzymes and is known to produce liver foci/tumors in mice and rats. From literature data, a mode of action (MOA) for PB-induced rodent liver tumor formation was developed. A MOA for PXR activators was not established owing to a lack of suitable data. The key events in the PB-induced liver tumor MOA comprise activation of CAR followed by altered gene expression specific to CAR activation, increased cell proliferation, formation of altered hepatic foci and ultimately the development of liver tumors. Associative events in the MOA include altered epigenetic changes, induction of hepatic CYP2B enzymes, liver hypertrophy and decreased apoptosis; with inhibition of gap junctional intercellular communication being an associative event or modulating factor. The MOA was evaluated using the modified Bradford Hill criteria for causality and other possible MOAs were excluded. While PB produces liver tumors in rodents, important species differences were identified including a lack of cell proliferation in cultured human hepatocytes. The MOA for PB-induced rodent liver tumor formation was considered to be qualitatively not plausible for humans. This conclusion is supported by data from a number of epidemiological studies conducted in human populations chronically exposed to PB in which there is no clear evidence for increased liver tumor risk.

Indexed as

AnimalsAryl Hydrocarbon HydroxylasesCell ProliferationConstitutive Androstane ReceptorCytochrome P-450 CYP2B6HepatocytesHumansLiverLiver NeoplasmsPhenobarbitalPregnane X ReceptorReceptors, Cytoplasmic and NuclearReceptors, SteroidXenobioticsAryl Hydrocarbon HydroxylasesConstitutive Androstane ReceptorCYP2B6 protein, humanCytochrome P-450 CYP2B6PhenobarbitalPregnane X ReceptorReceptors, Cytoplasmic and NuclearReceptors, SteroidXenobiotics

Identifiers

PMID24180433
PMCPMC4019974
OpenAlexW2057078403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.